Earle Burgess, MD
Hematology · Charlotte, NCNPI 1194872044
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,000 of the $75,268 with a category attached, or 78.4%. 11 manufacturers reported payments, led by Exelixis Inc. at 51.9% of the total. Reporting peaked in 2021 at $44,920 and has fallen 99.9% since, to $26 in 2025.
Across 63 payments — averaging $1194.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$39K
- AstraZeneca$15K
- Pfizer$8K
- Janssen Research & Development, LLC$8K
- Bayer$4K
- Merck$2K
- plus $337 from 5 others
Across 242 payments — averaging $13,836 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1M
- Janssen Research & Development, LLC$672K
- Genentech, Inc.$379K
- Seagen Inc.$368K
- Astellas Pharma Global Development$339K
- Pfizer$315K
- plus $237K from 4 others
What the payments were for
- Consulting fees$13,58318%
- Speaking & faculty fees$59,00078%
- Travel & lodging$1,4422%
- Food & beverage$1,1672%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 26 | $39,070 |
| AstraZeneca | 14 | $15,423 |
| Pfizer | 6 | $7,816 |
| Janssen Research & Development, LLC | 6 | $7,572 |
| Bayer | 2 | $3,524 |
| Merck | 2 | $1,526 |
| Novartis | 2 | $141 |
| Astellas Pharma Global Development | 2 | $106 |
| Boston Scientific | 1 | $50 |
| Urogen Pharma, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$34,190
- LYNPARZA$14,161
- Cabozantinib$4,620
- Nubeqa$1,844
- Non-Covered$1,680
- IMFINZI$1,230
How this compares
$75,268 in reported general payments places this provider in the 75th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 82 | $19,078 |
| Prednisone | 41 | $289 |
| Dexamethasone | 11 | $126 |
| Ondansetron Hcl | 11 | $75 |
Paid to pharmacies, not to this prescriber.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Omotayo FasanCharlotte$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.